prIME Rounds: Update on Immunotherapy for Head and Neck Cancer

prIME Rounds: Update on Immunotherapy for Head and Neck Cancer

View Activity

Activity Features


Downloadable Slides

Interactive Presentation

Activity Overview

This CME-certified prIME Rounds webcast centers on immunotherapy in head and neck cancer, focusing on the use of checkpoint inhibitors in squamous cell carcinoma of the head and neck.


  • Why targeting immune system in SCCHN
  • Use of immune checkpoint inhibitors in SCCHN in practice
  • Next steps in SCCHN


  • Ezra Cohen, MDUniversity of California at San Diego
    San Diego, California, United States

Target Audience

This educational activity is designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer.

Learning Objectives

After completion of this educational activity, participants should be able to:

  • Identify rationale and current indications for use of immune checkpoint inhibitors in recurrent and metastatic HNSCC
  • Explain unique patterns of response to immuno-oncology agents and management of immune-related adverse events
  • Assess the potential impact of biomarkers such as human papillomavirus (HPV) status, programmed death-ligand 1 (PD-L1), mutational load, and expression profiling on response to immunotherapy
  • Incorporate current and emerging immuno-oncology strategies to multidisciplinary care of head and neck cancer
View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and Disclosure Information


This educational activity is supported by a grant from Bristol-Myers Squibb.

Activity Date

December 22, 2017

December 22, 2018